Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations.

Details

Ressource 1Download: BIB_17BA49D0AEDA.P001.pdf (261.63 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_17BA49D0AEDA
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations.
Journal
NDT Plus
Author(s)
Carrera F., Burnier M.
ISSN
1753-0784 (Print)
ISSN-L
1753-0784
Publication state
Published
Issued date
2009
Volume
2
Number
Suppl .1
Pages
i9-i17
Language
english
Notes
Publication types: JOURNAL ARTICLEPublication Status: ppublish
Abstract
The introduction of erythropoiesis-stimulating agents (ESAs) into everyday clinical practice has greatly improved the care of patients with chronic kidney disease. ESAs have reduced the need for blood transfusions, improved survival, decreased cardiovascular complications and enhanced patient quality of life. The longer acting ESA, darbepoetin alfa (Aranesp(R)), which can be administered less frequently than traditional ESAs, provides further benefits to both patients and healthcare professionals relative to the epoetins. Clinical studies have shown that darbepoetin alfa administered once every 2 weeks or once every month allows enhanced convenience and cost savings with no compromise in efficacy, while maintaining patients within target haemoglobin ranges.
Keywords
blood , complications
Pubmed
Open Access
Yes
Create date
17/08/2009 14:33
Last modification date
20/08/2019 12:47
Usage data